Andrew Kai Kang, 10% Owner, Director, President, on July 13, 2026, executed a purchase for 272,405 shares in Robostrategy (BOT) for $9,999,988. Following the Form 4 filing with the SEC, Kang has control over a total of 9,581,372 common shares of the company, with 2,054,000 shares held directly and 7,527,372 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/2081119/000121390026078385/xslF345X05/ownership.xml
Stefan J. Murry, Chief Financial Officer, on July 10, 2026, sold 4,000 shares in Applied Optoelectronics (AAOI) for $488,360. Following the Form 4 filing with the SEC, Murry has control over a total of 380,576 common shares of the company, with 380,576 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1158114/000168316826005532/xslF345X05/ownership.xml
John E Kao, Director, Chief Executive Officer, on July 10, 2026, sold 298,000 shares in Alignment Healthcare (ALHC) for $5,919,361. Following the Form 4 filing with the SEC, Kao has control over a total of 2,697,509 common shares of the company, with 1,608,743 shares held directly and 1,088,766 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1832466/000162828026048170/xslF345X05/wk-form4_1784062026.xml
Martine A Rothblatt, Director, Chairperson & CEO, on July 13, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,091,949. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000097/xslF345X05/primarydocument.xml